BEYOND SPECIALTY DRUGS: Public and private payers are grappling with the rapid growth of high-cost treatments for rare diseases Posted onMay 15, 2017Authoradmin If the cost of the drug is half a million dollars per year or a million dollars per year, you can see that maybe nobody but Bill Gates or a few others can afford that.
